BRIEF-Verastem Oncology Announces Encouraging Preliminary Data From Ongoing Phase 1/2A Dose Escalation Trial Of Versus-7375, An Oral Kras G12d (On/Off) Inhibitor, In Patients With Kras G12d Mutant Solid Tumors
Reuters
Oct 24, 2025
BRIEF-<a href="https://laohu8.com/S/VSTM">Verastem</a> Oncology Announces Encouraging Preliminary Data From Ongoing Phase 1/2A Dose Escalation Trial Of Versus-7375, An Oral Kras G12d (On/Off) Inhibitor, In Patients With Kras G12d Mutant Solid Tumors
Oct 24 (Reuters) - Verastem Inc VSTM.O:
VERASTEM ONCOLOGY ANNOUNCES ENCOURAGING PRELIMINARY DATA FROM ONGOING PHASE 1/2A DOSE ESCALATION TRIAL OF VERSUS-7375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, IN PATIENTS WITH KRAS G12D MUTANT SOLID TUMORS
VERASTEM INC - FIRST TWO DOSE LEVELS CLEARED WITH NO DOSE-LIMITING TOXICITIES
VERASTEM INC - PROMISING ANTI-TUMOR ACTIVITY OBSERVED IN SOLID TUMORS
VERASTEM INC - INTERIM SAFETY AND EFFICACY UPDATE PLANNED FOR FIRST HALF OF 2026
Source text: ID:nBw3zP2Xna
Further company coverage: VSTM.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.